A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma

Luca Baldini, Andrea Guffanti, Paolo Gobbi, Mariangela Colombi, Massimo Federico, Paolo Avanzini, Luigi Cavanna, Carla Pieresca, Vittorio Silingardi, Anna T. Maiolo

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The role of intensive conventional dose chemotherapy in advanced low grade non-Hodgkin's lymphomas is a matter of debate. The Gruppo Italiano per lo Studio dei Linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, ProMACE- CytaBOM, as a first-line therapy in a selected group of patients with advanced follicular non-Hodgkin's lymphoma (Fo-NHL) who were younger than 60 years. METHODS. Thirty-nine patients were included in the study (14 males, 25 females; median age, 44 years; age range, 22-60 years). Their WF histotypes were B (9 patients), C (23 patients), and D (7 patients). All of the patients had disease in an advanced clinical stage (Stage III, 15 patients; Stage IV, 24 patients), and 9 patients had B symptoms. According to the age-adjusted International Prognostic Index (IPI), 20 patients exhibited low-intermediate risk, 14 high-intermediate risk, and 5 high risk. Three of the patients were not considered evaluable because they withdrew their consent after three (one patient) and four (two patients) cycles of therapy (one of these patients was in complete remission [CR], and two were in partial remission [PR]). Of the 36 evaluable patients, 4 received IF-RT after the 6 planned cycles of therapy. RESULTS. CR was achieved in 20 patients (55.5%) and PR in 14 (38.8%). One patient (2.7%) experienced disease progression during the treatment program. Eight of the 20 patients with CR (40%) relapsed. Eight patients (22.2%) died; 6 died of disease progression, 1 died of therapy consequences, and 1 died of an unrelated cause. With a median follow-up of 49 months (range, 28-79 months), the disease free survival rate was 60%. The overall survival rate was 80% after a median follow-up of 44 months (range, 3-79 months). The IPI stratification of patients showed a borderline statistical difference in terms of time to treatment failure and overall survival. The main hematologic toxicity was neutropenia (Grade 3 in approximately 10% of patients). One patient died of sepsis. Cotrimoxazole prophylaxis was always given. Cardiac toxicity (Grade 3) was observed in 1 patient at the end of the planned therapy. The average relative dose intensity of the drugs was 89% of the projected dose, without the regular use of growth factors. CONCLUSIONS. This study indicates that ProMACE-CytaBOM could be a suitable regimen for adult patients with advanced Fo-NHL, allowing a good CR rate and very good disease free survival rate. However, the occurrence of severe, albeit limited, adverse effects suggests that this regimen should first be used in controlled therapeutic protocols to verify its efficacy with respect to less intensive approaches.

Original languageEnglish
Pages (from-to)1234-1240
Number of pages7
JournalCancer
Volume79
Issue number6
DOIs
Publication statusPublished - Mar 15 1997

Fingerprint

Follicular Lymphoma
Non-Hodgkin's Lymphoma
Therapeutics
Survival Rate
Disease-Free Survival
Disease Progression

Keywords

  • advanced stages
  • follicular lymphoma
  • overall survival
  • ProMACE-CytaBOM regimen
  • therapeutic response
  • time to treatment failure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. / Baldini, Luca; Guffanti, Andrea; Gobbi, Paolo; Colombi, Mariangela; Federico, Massimo; Avanzini, Paolo; Cavanna, Luigi; Pieresca, Carla; Silingardi, Vittorio; Maiolo, Anna T.

In: Cancer, Vol. 79, No. 6, 15.03.1997, p. 1234-1240.

Research output: Contribution to journalArticle

Baldini, L, Guffanti, A, Gobbi, P, Colombi, M, Federico, M, Avanzini, P, Cavanna, L, Pieresca, C, Silingardi, V & Maiolo, AT 1997, 'A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma', Cancer, vol. 79, no. 6, pp. 1234-1240. https://doi.org/10.1002/(SICI)1097-0142(19970315)79:6<1234::AID-CNCR24>3.0.CO;2-#
Baldini, Luca ; Guffanti, Andrea ; Gobbi, Paolo ; Colombi, Mariangela ; Federico, Massimo ; Avanzini, Paolo ; Cavanna, Luigi ; Pieresca, Carla ; Silingardi, Vittorio ; Maiolo, Anna T. / A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. In: Cancer. 1997 ; Vol. 79, No. 6. pp. 1234-1240.
@article{2911641879064588adf6333247557009,
title = "A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma",
abstract = "BACKGROUND. The role of intensive conventional dose chemotherapy in advanced low grade non-Hodgkin's lymphomas is a matter of debate. The Gruppo Italiano per lo Studio dei Linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, ProMACE- CytaBOM, as a first-line therapy in a selected group of patients with advanced follicular non-Hodgkin's lymphoma (Fo-NHL) who were younger than 60 years. METHODS. Thirty-nine patients were included in the study (14 males, 25 females; median age, 44 years; age range, 22-60 years). Their WF histotypes were B (9 patients), C (23 patients), and D (7 patients). All of the patients had disease in an advanced clinical stage (Stage III, 15 patients; Stage IV, 24 patients), and 9 patients had B symptoms. According to the age-adjusted International Prognostic Index (IPI), 20 patients exhibited low-intermediate risk, 14 high-intermediate risk, and 5 high risk. Three of the patients were not considered evaluable because they withdrew their consent after three (one patient) and four (two patients) cycles of therapy (one of these patients was in complete remission [CR], and two were in partial remission [PR]). Of the 36 evaluable patients, 4 received IF-RT after the 6 planned cycles of therapy. RESULTS. CR was achieved in 20 patients (55.5{\%}) and PR in 14 (38.8{\%}). One patient (2.7{\%}) experienced disease progression during the treatment program. Eight of the 20 patients with CR (40{\%}) relapsed. Eight patients (22.2{\%}) died; 6 died of disease progression, 1 died of therapy consequences, and 1 died of an unrelated cause. With a median follow-up of 49 months (range, 28-79 months), the disease free survival rate was 60{\%}. The overall survival rate was 80{\%} after a median follow-up of 44 months (range, 3-79 months). The IPI stratification of patients showed a borderline statistical difference in terms of time to treatment failure and overall survival. The main hematologic toxicity was neutropenia (Grade 3 in approximately 10{\%} of patients). One patient died of sepsis. Cotrimoxazole prophylaxis was always given. Cardiac toxicity (Grade 3) was observed in 1 patient at the end of the planned therapy. The average relative dose intensity of the drugs was 89{\%} of the projected dose, without the regular use of growth factors. CONCLUSIONS. This study indicates that ProMACE-CytaBOM could be a suitable regimen for adult patients with advanced Fo-NHL, allowing a good CR rate and very good disease free survival rate. However, the occurrence of severe, albeit limited, adverse effects suggests that this regimen should first be used in controlled therapeutic protocols to verify its efficacy with respect to less intensive approaches.",
keywords = "advanced stages, follicular lymphoma, overall survival, ProMACE-CytaBOM regimen, therapeutic response, time to treatment failure",
author = "Luca Baldini and Andrea Guffanti and Paolo Gobbi and Mariangela Colombi and Massimo Federico and Paolo Avanzini and Luigi Cavanna and Carla Pieresca and Vittorio Silingardi and Maiolo, {Anna T.}",
year = "1997",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0142(19970315)79:6<1234::AID-CNCR24>3.0.CO;2-#",
language = "English",
volume = "79",
pages = "1234--1240",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma

AU - Baldini, Luca

AU - Guffanti, Andrea

AU - Gobbi, Paolo

AU - Colombi, Mariangela

AU - Federico, Massimo

AU - Avanzini, Paolo

AU - Cavanna, Luigi

AU - Pieresca, Carla

AU - Silingardi, Vittorio

AU - Maiolo, Anna T.

PY - 1997/3/15

Y1 - 1997/3/15

N2 - BACKGROUND. The role of intensive conventional dose chemotherapy in advanced low grade non-Hodgkin's lymphomas is a matter of debate. The Gruppo Italiano per lo Studio dei Linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, ProMACE- CytaBOM, as a first-line therapy in a selected group of patients with advanced follicular non-Hodgkin's lymphoma (Fo-NHL) who were younger than 60 years. METHODS. Thirty-nine patients were included in the study (14 males, 25 females; median age, 44 years; age range, 22-60 years). Their WF histotypes were B (9 patients), C (23 patients), and D (7 patients). All of the patients had disease in an advanced clinical stage (Stage III, 15 patients; Stage IV, 24 patients), and 9 patients had B symptoms. According to the age-adjusted International Prognostic Index (IPI), 20 patients exhibited low-intermediate risk, 14 high-intermediate risk, and 5 high risk. Three of the patients were not considered evaluable because they withdrew their consent after three (one patient) and four (two patients) cycles of therapy (one of these patients was in complete remission [CR], and two were in partial remission [PR]). Of the 36 evaluable patients, 4 received IF-RT after the 6 planned cycles of therapy. RESULTS. CR was achieved in 20 patients (55.5%) and PR in 14 (38.8%). One patient (2.7%) experienced disease progression during the treatment program. Eight of the 20 patients with CR (40%) relapsed. Eight patients (22.2%) died; 6 died of disease progression, 1 died of therapy consequences, and 1 died of an unrelated cause. With a median follow-up of 49 months (range, 28-79 months), the disease free survival rate was 60%. The overall survival rate was 80% after a median follow-up of 44 months (range, 3-79 months). The IPI stratification of patients showed a borderline statistical difference in terms of time to treatment failure and overall survival. The main hematologic toxicity was neutropenia (Grade 3 in approximately 10% of patients). One patient died of sepsis. Cotrimoxazole prophylaxis was always given. Cardiac toxicity (Grade 3) was observed in 1 patient at the end of the planned therapy. The average relative dose intensity of the drugs was 89% of the projected dose, without the regular use of growth factors. CONCLUSIONS. This study indicates that ProMACE-CytaBOM could be a suitable regimen for adult patients with advanced Fo-NHL, allowing a good CR rate and very good disease free survival rate. However, the occurrence of severe, albeit limited, adverse effects suggests that this regimen should first be used in controlled therapeutic protocols to verify its efficacy with respect to less intensive approaches.

AB - BACKGROUND. The role of intensive conventional dose chemotherapy in advanced low grade non-Hodgkin's lymphomas is a matter of debate. The Gruppo Italiano per lo Studio dei Linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, ProMACE- CytaBOM, as a first-line therapy in a selected group of patients with advanced follicular non-Hodgkin's lymphoma (Fo-NHL) who were younger than 60 years. METHODS. Thirty-nine patients were included in the study (14 males, 25 females; median age, 44 years; age range, 22-60 years). Their WF histotypes were B (9 patients), C (23 patients), and D (7 patients). All of the patients had disease in an advanced clinical stage (Stage III, 15 patients; Stage IV, 24 patients), and 9 patients had B symptoms. According to the age-adjusted International Prognostic Index (IPI), 20 patients exhibited low-intermediate risk, 14 high-intermediate risk, and 5 high risk. Three of the patients were not considered evaluable because they withdrew their consent after three (one patient) and four (two patients) cycles of therapy (one of these patients was in complete remission [CR], and two were in partial remission [PR]). Of the 36 evaluable patients, 4 received IF-RT after the 6 planned cycles of therapy. RESULTS. CR was achieved in 20 patients (55.5%) and PR in 14 (38.8%). One patient (2.7%) experienced disease progression during the treatment program. Eight of the 20 patients with CR (40%) relapsed. Eight patients (22.2%) died; 6 died of disease progression, 1 died of therapy consequences, and 1 died of an unrelated cause. With a median follow-up of 49 months (range, 28-79 months), the disease free survival rate was 60%. The overall survival rate was 80% after a median follow-up of 44 months (range, 3-79 months). The IPI stratification of patients showed a borderline statistical difference in terms of time to treatment failure and overall survival. The main hematologic toxicity was neutropenia (Grade 3 in approximately 10% of patients). One patient died of sepsis. Cotrimoxazole prophylaxis was always given. Cardiac toxicity (Grade 3) was observed in 1 patient at the end of the planned therapy. The average relative dose intensity of the drugs was 89% of the projected dose, without the regular use of growth factors. CONCLUSIONS. This study indicates that ProMACE-CytaBOM could be a suitable regimen for adult patients with advanced Fo-NHL, allowing a good CR rate and very good disease free survival rate. However, the occurrence of severe, albeit limited, adverse effects suggests that this regimen should first be used in controlled therapeutic protocols to verify its efficacy with respect to less intensive approaches.

KW - advanced stages

KW - follicular lymphoma

KW - overall survival

KW - ProMACE-CytaBOM regimen

KW - therapeutic response

KW - time to treatment failure

UR - http://www.scopus.com/inward/record.url?scp=0030894140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030894140&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970315)79:6<1234::AID-CNCR24>3.0.CO;2-#

DO - 10.1002/(SICI)1097-0142(19970315)79:6<1234::AID-CNCR24>3.0.CO;2-#

M3 - Article

C2 - 9070503

AN - SCOPUS:0030894140

VL - 79

SP - 1234

EP - 1240

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -